Biodesix Inc (BDSX)vsMerck & Company Inc (MRK)
BDSX
Biodesix Inc
$23.50
+6.33%
HEALTHCARE · Cap: $221.51M
MRK
Merck & Company Inc
$128.57
+0.16%
HEALTHCARE · Cap: $316.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 68340% more annual revenue ($65.77B vs $96.10M). MRK leads profitability with a 13.6% profit margin vs -33.3%. MRK earns a higher WallStSmart Score of 50/100 (D+).
BDSX
Avoid29
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-15.9%
Fair Value
$8.93
Current Price
$23.50
$14.57 premium
Margin of Safety
-58.0%
Fair Value
$81.23
Current Price
$128.57
$47.34 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 42.3% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 26.1x book value
ROE of -349.9% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BDSX
The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 42.3% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : BDSX
The primary concerns for BDSX are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 7.84 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
BDSX profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
BDSX carries more volatility with a beta of 0.52 — expect wider price swings.
BDSX is growing revenue faster at 42.3% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biodesix Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?